MA29020B1 - Composition contenant une vlp et un peptide amyloide beta - Google Patents

Composition contenant une vlp et un peptide amyloide beta

Info

Publication number
MA29020B1
MA29020B1 MA29899A MA29899A MA29020B1 MA 29020 B1 MA29020 B1 MA 29020B1 MA 29899 A MA29899 A MA 29899A MA 29899 A MA29899 A MA 29899A MA 29020 B1 MA29020 B1 MA 29020B1
Authority
MA
Morocco
Prior art keywords
composition containing
amyloid peptide
beta amyloid
containing vlp
vlp
Prior art date
Application number
MA29899A
Other languages
English (en)
French (fr)
Inventor
Ana Graf
Matthias Staufenbiel
Thomas Blaettler
Paolo Paganetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33523293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29020(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29020B1 publication Critical patent/MA29020B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA29899A 2004-11-05 2007-05-14 Composition contenant une vlp et un peptide amyloide beta MA29020B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0424563A GB0424563D0 (en) 2004-11-05 2004-11-05 Organic compounds

Publications (1)

Publication Number Publication Date
MA29020B1 true MA29020B1 (fr) 2007-11-01

Family

ID=33523293

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29899A MA29020B1 (fr) 2004-11-05 2007-05-14 Composition contenant une vlp et un peptide amyloide beta

Country Status (25)

Country Link
US (4) US7867499B2 (https=)
EP (2) EP2286830A3 (https=)
JP (2) JP2008515954A (https=)
KR (1) KR20070073882A (https=)
CN (1) CN101048174A (https=)
AR (1) AR054092A1 (https=)
AU (2) AU2005300692A1 (https=)
BR (1) BRPI0517682A (https=)
CA (1) CA2581300A1 (https=)
EC (1) ECSP077415A (https=)
GB (1) GB0424563D0 (https=)
GT (1) GT200500313A (https=)
IL (1) IL182692A (https=)
MA (1) MA29020B1 (https=)
MX (1) MX2007005430A (https=)
MY (1) MY148584A (https=)
NO (1) NO20072743L (https=)
NZ (1) NZ583688A (https=)
PE (1) PE20061047A1 (https=)
RU (1) RU2415677C2 (https=)
SG (1) SG170646A1 (https=)
TN (1) TNSN07166A1 (https=)
TW (1) TWI380825B (https=)
WO (1) WO2006048295A1 (https=)
ZA (1) ZA200702369B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
BR112012024708A2 (pt) * 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0038154B1 (en) 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01501064A (ja) 1986-09-22 1989-04-13 エモリ　ユニバーシティ ワクチンとその製法
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5142726A (en) * 1991-04-03 1992-09-01 Mann Robert F Adjustable bristle length toothbrush
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US6180771B1 (en) 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
JPH09202735A (ja) 1996-01-25 1997-08-05 Nof Corp リポソーム型アレルギー治療薬
US5786161A (en) 1996-06-06 1998-07-28 Miltenyi Biotec. Gmbh Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity
SE9604815D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
WO1999040934A1 (en) 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
EA004497B1 (ru) 1998-12-04 2004-04-29 Байоджен, Инк. Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
CN1520423A (zh) 1999-02-25 2004-08-11 ʷ��˿�������ȳ�ķ���޹�˾ 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001053457A2 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US8519005B2 (en) * 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219459A1 (en) 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
MXPA04011247A (es) 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.
SI1524994T1 (sl) * 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
WO2004016262A1 (ja) 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2011157395A (ja) 2011-08-18
US20090060899A1 (en) 2009-03-05
ECSP077415A (es) 2007-05-30
AU2010200410B2 (en) 2011-10-13
EP2286830A3 (en) 2011-03-30
TW200621288A (en) 2006-07-01
US20130252889A1 (en) 2013-09-26
IL182692A0 (en) 2007-09-20
TNSN07166A1 (en) 2008-11-21
US8460676B2 (en) 2013-06-11
US7867499B2 (en) 2011-01-11
KR20070073882A (ko) 2007-07-10
RU2007120689A (ru) 2008-12-20
BRPI0517682A (pt) 2008-10-14
CN101048174A (zh) 2007-10-03
RU2415677C2 (ru) 2011-04-10
GB0424563D0 (en) 2004-12-08
JP2008515954A (ja) 2008-05-15
CA2581300A1 (en) 2006-05-11
US20110086036A1 (en) 2011-04-14
GT200500313A (es) 2006-12-18
AR054092A1 (es) 2007-06-06
AU2010200410A1 (en) 2010-02-25
US20140079730A1 (en) 2014-03-20
NO20072743L (no) 2007-05-30
AU2005300692A1 (en) 2006-05-11
NZ583688A (en) 2011-10-28
EP1812050A1 (en) 2007-08-01
PE20061047A1 (es) 2006-11-07
IL182692A (en) 2010-12-30
MY148584A (en) 2013-04-30
MX2007005430A (es) 2007-05-18
WO2006048295A1 (en) 2006-05-11
SG170646A1 (en) 2011-05-30
ZA200702369B (en) 2008-09-25
US8617566B2 (en) 2013-12-31
EP2286830A2 (en) 2011-02-23
TWI380825B (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
BRPI0511900A (pt) composições farmacêuticas
PL1954684T3 (pl) Związek oksazolowy i kompozycja farmaceutyczna
EP1967126A4 (en) CONTAINER DEVICE
DE602005012035D1 (de) Kontrast-Verstärkung
CY2014039I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
DK1991563T3 (da) Peptidsekvenser og sammensætninger
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
DE602005015131D1 (de) Interleukin-15-antagonistisches peptid
IL184609A0 (en) Compositions containing an antigen and an adjuvent peptide
DE602004000946D1 (de) Dimethylpolysiloxan -Zusammensetzung
MA29020B1 (fr) Composition contenant une vlp et un peptide amyloide beta
PL2851068T3 (pl) Kompozycja zawierająca NLPZ oraz paracetamol
DE602004030951D1 (de) Rückseitendünnung von bild-array-einrichtungen
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
EP1875902A4 (en) MEDIUM SUSPENSIONING EFFECT AND THIS CONTAINING MOISTURIZING FRUIT COMPOSITION
DK1709082T3 (da) Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
FR2881342B1 (fr) Composition demaquillante
DE602005023720D1 (de) Acrylelastomerzusammensetzung
ITMI20042232A1 (it) Composizione farmaceutica contenente clozapina
BRPI0810057A2 (pt) Composição farmacêutica contendo floroglucinol e paracetamol
EP1852411A4 (en) TRIFLUORO NAPHTHALIN DERIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING THE COMPOUND
DK1784174T3 (da) Famaceutisk sammensætning omfattende gabapentin
FR2871686B1 (fr) Composition anti-decoloration
EP1736488A4 (en) FLUORPOLYMER CONTAINING STAIN REMOVER